Results 81 to 90 of about 1,075,360 (295)
Molecular Oncology, EarlyView.Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen +9 more
wiley +1 more source
Tumor Biology, 2017 Emerging evidence has demonstrated that the high expression of HBXIP has been correlated with many cancers. With evaluation of the functional role of HBXIP in non-small-cell lung cancer, the primary aim of this study is to investigate the correlation ...
Yixuan Wang +6 more
doaj +1 more source
A tüdőrák molekuláris patológiai vizsgálatának feltételei [PDF]
, 2016 From the aspect of the contemporary pathologic diagnostics of lung cancer the tissue obtained is a key issue since small biopsies and cytology still play a major role.
Tímár József
core
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer. [PDF]
, 2016 Dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) is a member of dual-specificity kinase family, which could phosphorylate both Ser/Thr and Tyr substrates. The role of DYRK2 in human cancer remains controversial.
Chu, Zhonghua +7 more
core +2 more sources
Molecular cancer prevention: Intercepting disease
Molecular Oncology, EarlyView.Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco +2 more
wiley +1 more source
Chemotherapy for advanced non-small-cell lung cancer: Role of paclitaxel and gemcitabine [PDF]
, 1999 Objective. To review the role of chemotherapy in advanced non-small-cell lung cancer, focusing on cisplatin-based regimens and two new drugs: paclitaxel and gemcitabine. Data sources. Medline search of the relevant English literature.
Ip, MSM, Lam, WK, Tsang, KWT
core
Exploring a structural protein-drug interactome for new therapeutics in lung cancer [PDF]
, 2014 The pharmacology of drugs is often defined by more than one protein target. This property can be exploited to use approved drugs to uncover new targets and signaling pathways in cancer.
Bum-Erdene, Khuchtumur +12 more
core +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Afatinib treatment in advanced non-small cell lung cancer
Lung Cancer: Targets and Therapy, 2011 Jane L Hurwitz, Paula Scullin, Lynn CampbellDepartment of Medical Oncology, Northern Ireland Cancer Centre, Belfast, UKAbstract: Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients ...
Hurwitz JL, Scullin P, Campbell L
doaj
Immunotherapy in inoperable stage III non-small cell lung cancer: a review
Drugs in Context, 2019 The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25–30% of patients are diagnosed with locally advanced nonsmall cell lung cancer (NSCLC).
Natasha A Jain, Gregory A Otterson
doaj +1 more source